Neurobiology of bipolar disorder

References

• Goodwin FK, Jamison KR. Conceptualizing manic–depressive illness: the bipolar–unipolar distinction and the development of the manic–depressive spectrum. In: Manic–Depressive Illness: The Bipolar Disorders and Recurrent Depression (2nd Edition). Oxford University Press, NY, USA 3–27 (2007).
   Google Scholar
• Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ. A cholinergic–adrenergic hypothesis of mania and depression. Lancet2(7778), 632–635 (1972).
   PubMed Web of Science ®Google Scholar
• Post RM, Rubinow DR, Ballenger JC. Conditioning, Sensitization, and Kindling: Implications for the Course of Affective Illness. Post RM, Ballenger JC (Eds). Williams & Wilkins, MD, USA 432–466 (1984).
   Google Scholar
• Goodwin FK, Jamison KR.Neurobiology. In: Manic–Depressive Illness: The Bipolar Disorders And Recurrent Depression (2nd Edition). Oxford University Press, NY, USA, 463–607 (2007).
   Google Scholar
• Fagiolini A, Kupfer DJ, Masalehdan A, Scott JA, Houck PR, Frank E. Functional impairment in the remission phase of bipolar disorder. Bipolar Disord.7(3), 281–285 (2005).
   PubMed Web of Science ®Google Scholar
• Revicki DA, Matza LS, Flood E, Lloyd A. Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials. Pharmacoeconomics23(6), 583–594 (2005).
   PubMed Web of Science ®Google Scholar
• Tohen M, Zarate CA Jr, Hennen J et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am. J. Psychiatry160(12), 2099–2107 (2003).
   PubMed Web of Science ®Google Scholar
• Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA293(20), 2528–2530 (2005).
   PubMed Web of Science ®Google Scholar
• Catapano LA, Manji HK. G protein-coupled receptors in major psychiatric disorders. Biochim. Biophys. Acta1768(4), 976–993 (2007).
   PubMedGoogle Scholar
• Zarate CA Jr, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol. Psychiatry59(11), 1006–1020 (2006).
   PubMed Web of Science ®Google Scholar
• Sanacora G, Mason GF, Rothman DL et al. Reduced cortical β-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry56(11), 1043–1047 (1999).
   PubMed Web of Science ®Google Scholar
• Krystal JH, Sanacora G, Blumberg H et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry7(Suppl. 1), S711–S80 (2002).
   PubMed Web of Science ®Google Scholar
• Dean B, Scarr E, McLeod M. Changes in hippocampal GABAA receptor subunit composition in bipolar 1 disorder. Brain Res. Mol. Brain Res.138(2), 145–155 (2005).
   PubMedGoogle Scholar
• Guidotti A, Auta J, Davis JM et al. Decrease in reelin and glutamic acid decarboxylase 67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch. Gen. Psychiatry57(11), 1061–1069 (2000).
   PubMed Web of Science ®Google Scholar
• Johannessen CU. Mechanisms of action of valproate: a commentatory. Neurochem. Int.37(2–3), 103–110 (2000).
   PubMed Web of Science ®Google Scholar
• McEwen BS. Stress and hippocampal plasticity. Annu. Rev. Neurosci.22, 105–122 (1999).
   PubMed Web of Science ®Google Scholar
• Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry57(10), 925–935 (2000).
   PubMed Web of Science ®Google Scholar
• Castillo M, Kwock L, Courvoisie H, Hooper SR. Proton MR spectroscopy in children with bipolar affective disorder: preliminary observations. AJNR Am. J. Neuroradiol.21(5), 832–838 (2000).
   PubMed Web of Science ®Google Scholar
• Sanacora G, Gueorguieva R, Epperson CN et al. Subtype-specific alterations of β-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry61(7), 705–713 (2004).
   PubMed Web of Science ®Google Scholar
• Dixon JF, Hokin LE. Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex. Proc. Natl Acad. Sci. USA95(14), 8363–8368 (1998).
   PubMed Web of Science ®Google Scholar
• Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport9(9), 2081–2084 (1998).
   PubMed Web of Science ®Google Scholar
• Kunig G, Niedermeyer B, Deckert J, Gsell W, Ransmayr G, Riederer P. Inhibition of 3H α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid [AMPA] binding by the anticonvulsant valproate in clinically relevant concentrations: an autoradiographic investigation in human hippocampus. Epilepsy Res.31(2), 153–157 (1998).
   PubMedGoogle Scholar
• Du J, Gray NA, Falke C, Yuan P, Szabo S, Manji HK. Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression. Ann. NY Acad. Sci.1003, 378–380 (2003).
   PubMed Web of Science ®Google Scholar
• Du J, Creson T, Gray N et al. The role of hippocampal GluR1 and GluR2 receptors in manic-like behaviors. J. Neurosci. (2007) (In Press).
   Google Scholar
• Loscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol.58(1), 31–59 (1999).
   PubMed Web of Science ®Google Scholar
• Ueda Y, Willmore LJ. Molecular regulation of glutamate and GABA transporter proteins by valproic acid in rat hippocampus during epileptogenesis. Exp. Brain Res.133(3), 334–339 (2000).
   PubMedGoogle Scholar
• Hassel B, Iversen EG, Gjerstad L, Tauboll E. Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate. J. Neurochem.77(5), 1285–1292 (2001).
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Carlson PJ et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry63(8), 856–864 (2006).
   PubMed Web of Science ®Google Scholar
• Sanacora G, Kendell SF, Levin Y et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol. Psychiatry61(6), 822–825 (2007).
   PubMed Web of Science ®Google Scholar
• Prange A, Lara P, Alltop P. Effects of thyrotropin-releasing hormones in depression. In: The Thyroid Axis, Drugs and Behavior. Prange A (Ed.). Raven Press, NY, USA 135–145 (1974).
   Google Scholar
• Joyce PR. The prognostic significance of thyroid function in mania. J. Psychiatric Res.25(1–2), 1–6 (1991).
   PubMedGoogle Scholar
• Styra R, Joffe R, Singer W. Hyperthyroxinemia in major affective disorders. Acta Psychiatr. Scand.83(1), 61–63 (1991).
   PubMedGoogle Scholar
• Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am. J. Psychiatry145(2), 179–184 (1988).
   PubMed Web of Science ®Google Scholar
• Zach J, Ackerman SH. Thyroid function, metabolic regulation, and depression. Psychosomatic Med.50(5), 454–468 (1988).
   PubMed Web of Science ®Google Scholar
• Hendrick V, Altshuler L, Whybrow P. Psychoneuroendocrinology of mood disorders. The hypothalamic–pituitary– thyroid axis. Psychiatric Clin. North Am.21(2), 277–292 (1998).
   PubMed Web of Science ®Google Scholar
• Goodwin FK, Prange AJ Jr, Post RM, Muscettola G, Lipton MA. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am. J. Psychiatry139(1), 34–38 (1982).
   PubMed Web of Science ®Google Scholar
• Josephson AM, Mackenzie TB. Appearance of manic psychosis following rapid normalization of thyroid status. Am. J. Psychiatry136(6), 846–847 (1979).
   PubMedGoogle Scholar
• Josephson AM, Mackenzie TB. Thyroid-induced mania in hypothyroid patients. Br. J. Psychiatry137, 222–228 (1980).
   PubMed Web of Science ®Google Scholar
• Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am. J. Psychiatry144(11), 1403–1411 (1987).
   Google Scholar
• Afflelou S, Auriacombe M, Cazenave M, Chartres JP, Tignol J. [Administration of high dose levothyroxine in treatment of rapid cycling bipolar disorders. Review of the literature and initial therapeutic application apropos of 6 cases. Encephale23(3), 209–217 (1997).
   PubMedGoogle Scholar
• Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch. Gen. Psychiatry47(5), 435–440 (1990).
   PubMed Web of Science ®Google Scholar
• Zarate CA, Tohen M, Zarate SB. Thyroid function tests in first-episode bipolar disorder manic and mixed types. Biol. Psychiatry42(4), 302–304 (1997).
   PubMedGoogle Scholar
• Griffiths EC. Thyrotrophin releasing hormone: endocrine and central effects. Psychoneuroendocrinology10(3), 225–235 (1985).
   PubMed Web of Science ®Google Scholar
• Krystal A, Krishnan KR, Raitiere M et al. Differential diagnosis and pathophysiology of Cushing’s syndrome and primary affective disorder. J. Neuropsychiatry Clin. Neurosci.2(1), 34–43 (1990).
   PubMedGoogle Scholar
• Sonino N, Fava GA. Psychiatric disorders associated with Cushing’s syndrome. Epidemiology, pathophysiology and treatment. CNS Drugs15(5), 361–373 (2001).
   PubMed Web of Science ®Google Scholar
• Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology29(8), 1538–1545 (2004).
   PubMed Web of Science ®Google Scholar
• Board F, Wadeson R, Persky H. Depressive affect and endocrine functions; blood levels of adrenal cortex and thyroid hormones in patients suffering from depressive reactions. AMA Arch. Neurol. Psychiatry78(6), 612–620 (1957).
   PubMedGoogle Scholar
• Gibbons JL. Cortisol secretion rate in depressive illness. Arch. Gen. Psychiatry10, 572–575 (1964).
   PubMed Web of Science ®Google Scholar
• Sachar EJ, Hellman L, Roffwarg HP, Halpern FS, Fukushima DK, Gallagher TF. Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Arch. Gen. Psychiatry28(1), 19–24 (1973).
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Tighe S, McVey G, Brown GM. Melatonin and cortisol “switches” during mania, depression, and euthymia in a drug-free bipolar patient. J. Mental Dis.177(5), 300–303 (1989).
   PubMed Web of Science ®Google Scholar
• Bunney WE Jr, Mason JW, Hamburg DA. Correlations between behavioral variables and urinary 17-hydroxycorticosteroids in depressed patients. Psychosomatic Med.27, 299–308 (1965).
   PubMedGoogle Scholar
• McEwen BS. Stress and the aging hippocampus. Front. Neuroendocrinol.20(1), 49–70 (1999).
   PubMed Web of Science ®Google Scholar
• McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res.886(1–2), 172–189 (2000).
   PubMed Web of Science ®Google Scholar
• Fink M, Bolwig TG, Parker G, Shorter E. Melancholia: restoration in psychiatric classification recommended. Acta Psychiatr. Scand.115(2), 89–92 (2007).
   PubMed Web of Science ®Google Scholar
• Bolwig TG, Madsen TM. Electroconvulsive therapy in melancholia: the role of hippocampal neurogenesis. Acta Psychiatr. Scand. Suppl.433, 130–135 (2007).
   Google Scholar
• Webster MJ, Knable MB, O’Grady J, Orthmann J, Weickert CS. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol. Psychiatry7(9), 985–994, 924 (2002).
   PubMed Web of Science ®Google Scholar
• Xing GQ, Russell S, Webster MJ, Post RM. Decreased expression of mineralocorticoid receptor mRNA in the prefrontal cortex in schizophrenia and bipolar disorder. Int. J. Neuropsychopharmacol.7(2), 143–153 (2004).
   PubMed Web of Science ®Google Scholar
• Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H. Mineralocorticoid receptor function in major depression. Arch. Gen. Psychiatry60(1), 24–28 (2003).
   PubMed Web of Science ®Google Scholar
• Malison RT, Anand A, Pelton GH et al. Limited efficacy of ketoconazole in treatment-refractory major depression. J. Clin. Psychopharmacol.19(5), 466–470 (1999).
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Reus VI, Chan T et al. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol. Psychiatry45(8), 1070–1074 (1999).
   PubMed Web of Science ®Google Scholar
• Young AH. Antiglucocoticoid treatments for depression. Aus. NZ J. Psychiatry40(5), 402–405 (2006).
   PubMed Web of Science ®Google Scholar
• Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol.21(5), 516–521 (2001).
   PubMed Web of Science ®Google Scholar
• DeBattista C, Posener JA, Kalehzan BM, Schatzberg AF. Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. Am. J. Psychiatry157(8), 1334–1337 (2000).
   PubMed Web of Science ®Google Scholar
• Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biol. Psychiatry45(12), 1533–1541 (1999).
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Reus VI, Keebler A et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am. J. Psychiatry156(4), 646–649 (1999).
   PubMed Web of Science ®Google Scholar
• Mansbach RS, Brooks EN, Chen YL. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur. J. Pharmacol.323(1), 21–26 (1997).
   PubMed Web of Science ®Google Scholar
• Zobel AW, Nickel T, Kunzel HE et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatric Res.34(3), 171–181 (2000).
   PubMed Web of Science ®Google Scholar
• Ram A, Guedj F, Cravchik A et al. No abnormality in the gene for the G protein stimulatory α subunit in patients with bipolar disorder. Arch. Gen. Psychiatry54(1), 44–48 (1997).
   PubMedGoogle Scholar
• Wang J-F, Young LT, Li PP, Warsh JJ. Signal transduction abnormalities in bipolar disorder. In: Bipolar Disorder: Biological Models and their Clinical Application. Joffe RT (Ed.). Dekker, NY, USA 41–79 (1997).
   Google Scholar
• Warsh J, Young L, Li P. Guanine nucleotide binding (g) protein disturbances. In: Bipolar Affective Disorder in Bipolar Medications: Mechanisms of Action. Belmaker R (Ed.). American Psychiatric Press, Washington, DC, USA 299–329 (2000).
   Google Scholar
• Perez J, Tardito D, Mori S, Racagni G, Smeraldi E, Zanardi R. Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder. Arch. Gen. Psychiatry56(3), 248–253 (1999).
   PubMed Web of Science ®Google Scholar
• Rahman S, Li PP, Young LT, Kofman O, Kish SJ, Warsh JJ. Reduced 3H cyclic AMP binding in postmortem brain from subjects with bipolar affective disorder. J. Neurochem.68(1), 297–304 (1997).
   PubMed Web of Science ®Google Scholar
• Manji HK, Chen G, Shimon H, Hsiao JK, Potter WZ, Belmaker RH. Guanine nucleotide-binding proteins in bipolar affective disorder. Effects of long-term lithium treatment. Arch. Gen. Psychiatry52(2), 135–144 (1995).
   PubMedGoogle Scholar
• Jope RS. A bimodal model of the mechanism of action of lithium. Mol. Psychiatry4(1), 21–25 (1999).
   PubMedGoogle Scholar
• Chen G, Pan B, Hawver DB, Wright CB, Potter WZ, Manji HK. Attenuation of cyclic AMP production by carbamazepine. J. Neurochem.67(5), 2079–2086 (1996).
   PubMed Web of Science ®Google Scholar
• Montezinho LP, Mork A, Duarte CB, Penschuck S, Geraldes CF, Castro MM. Effects of mood stabilizers on the inhibition of adenylate cyclase via dopamine D2-like receptors. Bipolar Disord.9(3), 290–297 (2007).
   PubMedGoogle Scholar
• Allison JH, Stewart MA. Reduced brain inositol in lithium-treated rats. Nat. New Biol.233(43), 267–268 (1971).
   PubMedGoogle Scholar
• Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J. Biol. Chem.255(22), 10896–10901 (1980).
   PubMed Web of Science ®Google Scholar
• Baum AE, Akula N, Cabanero M et al. A Genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol. Psychiatry (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Shaltiel G, Dalton EC, Belmaker RH, Harwood AJ, Agam G. Specificity of mood stabilizer action on neuronal growth cones. Bipolar Disord.9(3), 281–289 (2007).
   PubMedGoogle Scholar
• van Calker D, Belmaker RH. The high affinity inositol transport system – implications for the pathophysiology and treatment of bipolar disorder. Bipolar Disord.2(2), 102–107 (2000).
   PubMedGoogle Scholar
• Willmroth F, Drieling T, Lamla U, Marcushen M, Wark HJ, van Calker D. Sodium-myo-inositol co-transporter (SMIT-1) mRNA is increased in neutrophils of patients with bipolar 1 disorder and down-regulated under treatment with mood stabilizers. Int. J. Neuropsychopharmacol.10(1), 63–71 (2007).
   PubMed Web of Science ®Google Scholar
• Wang JF, Asghari V, Rockel C, Young LT. Cyclic AMP responsive element binding protein phosphorylation and DNA binding is decreased by chronic lithium but not valproate treatment of SH-SY5Y neuroblastoma cells. Neuroscience91(2), 771–776 (1999).
   PubMedGoogle Scholar
• Chen G, Masana MI, Manji HK. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord.2(3 Pt 2), 217–236 (2000).
   PubMedGoogle Scholar
• Lenox RH, Watson DG, Patel J, Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res.570(1–2), 333–340 (1992).
   PubMedGoogle Scholar
• Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch. Gen. Psychiatry57(1), 95–97 (2000).
   PubMed Web of Science ®Google Scholar
• Kulkarni J, Garland KA, Scaffidi A et al. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology31(4), 543–547 (2006).
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Carlson PJ et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord.9(6), 561–570 (2007).
   PubMed Web of Science ®Google Scholar
• Manji HK, Lenox RH. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol. Psychiatry46(10), 1328–1351 (1999).
   PubMed Web of Science ®Google Scholar
• Lenox RH, Hahn CG. Overview of the mechanism of action of lithium in the brain: fifty-year update. J. Clin. Psychiatry61(Suppl. 9), 5–15 (2000).
   PubMed Web of Science ®Google Scholar
• Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology30(7), 1223–1237 (2005).
   PubMed Web of Science ®Google Scholar
• Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3β, mood stabilizers, and neuroprotection. Bipolar Disord.4(2), 137–144 (2002).
   PubMed Web of Science ®Google Scholar
• Schloesser RJ, Huang J, Klein PS, Manji HK. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology (2007).
   Google Scholar
• Manji HK, Duman RS. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol. Bull.35(2), 5–49 (2001).
   PubMedGoogle Scholar
• Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive–emotional features of mood disorders. Curr. Opin. Neurobiol.11(2), 240–249 (2001).
   PubMed Web of Science ®Google Scholar
• Beyer JL, Krishnan KR. Volumetric brain imaging findings in mood disorders. Bipolar Disord.4(2), 89–104 (2002).
   PubMed Web of Science ®Google Scholar
• Strakowski SM, Adler CM, DelBello MP. Volumetric MRI studies of mood disorders: do they distinguish unipolar and bipolar disorder? Bipolar Disord.4(2), 80–88 (2002).
   PubMed Web of Science ®Google Scholar
• Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl Acad. Sci. USA95(22), 13290–13295 (1998).
   PubMed Web of Science ®Google Scholar
• Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch. Gen. Psychiatry58(6), 545–553 (2001).
   PubMed Web of Science ®Google Scholar
• Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol. Psychiatry48(8), 766–777 (2000).
   PubMed Web of Science ®Google Scholar
• Uranova N, Orlovskaya D, Vikhreva O et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res. Bull.55(5), 597–610 (2001).
   PubMed Web of Science ®Google Scholar
• Tkachev D, Mimmack ML, Ryan MM et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet362(9386), 798–805 (2003).
   PubMed Web of Science ®Google Scholar
• Carlson PJ, Singh JB, Zarate CA Jr, Drevets WC, Manji HK. Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx3(1), 22–41 (2006).
   PubMedGoogle Scholar
• Chen G, Manji HK. The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers. Curr. Opin. Psychiatry19(3), 313–323 (2006).
   PubMedGoogle Scholar
• Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord.2(3 Pt 1), 180–190 (2000).
   PubMed Web of Science ®Google Scholar
• Kato T. The other, forgotten genome: mitochondrial DNA and mental disorders. Mol. Psychiatry6(6), 625–633 (2001).
   PubMed Web of Science ®Google Scholar
• Kato T, Ishiwata M, Mori K et al. Mechanisms of altered Ca2+ signalling in transformed lymphoblastoid cells from patients with bipolar disorder. Int. J. Neuropsychopharmacol.6(4), 379–389 (2003).
   PubMed Web of Science ®Google Scholar
• Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch. Gen. Psychiatry61(3), 300–308 (2004).
   PubMed Web of Science ®Google Scholar
• Einat H, Manji HK, Belmaker RH. New approaches to modeling bipolar disorder. Psychopharmacol. Bull.37(1), 47–63 (2003).
   PubMedGoogle Scholar
• Hao Y, Creson T, Zhang L et al. Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J. Neurosci.24(29), 6590–6599 (2004).
   PubMed Web of Science ®Google Scholar
• Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic–depressive illness. Biol. Psychiatry48(8), 740–754 (2000).
   PubMed Web of Science ®Google Scholar
• Zhou R, Gray NA, Yuan P et al. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J. Neurosci.25(18), 4493–4502 (2005).
   PubMed Web of Science ®Google Scholar
• Maeng S, Wei Y, McCammon J et al. BAG1 plays a critical role in regulating affective resilience. Proc. Natl Acad. Sci. USA (2007) (In Press).
   Google Scholar
• Wei H, Qin ZH, Senatorov VV et al. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington’s disease. Neuroscience106(3), 603–612 (2001).
   PubMedGoogle Scholar
• Huang X, Wu DY, Chen G, Manji H, Chen DF. Support of retinal ganglion cell survival and axon regeneration by lithium through a Bcl-2-dependent mechanism. Invest. Ophthalmol. Vis. Sci.44(1), 347–354 (2003).
   PubMedGoogle Scholar
• Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J. Neurochem.75(4), 1729–1734 (2000).
   PubMed Web of Science ®Google Scholar
• Kim JS, Chang MY, Yu IT et al. Lithium selectively increases neuronal differentiation of hippocampal neural progenitor cells both in vitro and in vivo. J. Neurochem.89(2), 324–336 (2004).
   PubMed Web of Science ®Google Scholar
• Kuhn HG, Biebl M, Wilhelm D, Li M, Friedlander RM, Winkler J. Increased generation of granule cells in adult Bcl-2-overexpressing mice: a role for cell death during continued hippocampal neurogenesis. Eur. J. Neurosci.22(8), 1907–1915 (2005).
   PubMedGoogle Scholar
• Moore CM, Biederman J, Wozniak J et al. Differences in brain chemistry in children and adolescents with attention deficit hyperactivity disorder with and without comorbid bipolar disorder: a proton magnetic resonance spectroscopy study. Am. J. Psychiatry163(2), 316–318 (2006).
   PubMed Web of Science ®Google Scholar
• Vollmayr B, Mahlstedt MM, Henn FA. Neurogenesis and depression: what animal models tell us about the link. Eur. Arch. Psychiatry Clin. Neurosci.257(5), 300–303 (2007).
   PubMed Web of Science ®Google Scholar
• Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Ann. Rev. Pharmacol. Toxicol.45, 495–528 (2005).
   PubMed Web of Science ®Google Scholar
• Langley B, Gensert JM, Beal MF, Ratan RR. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Current Drug Targets4(1), 41–50 (2005).
   Google Scholar
• Kato T. Molecular genetics of bipolar disorder and depression. Psychiatry Clin. Neurosci.61(1), 3–19 (2007).
   PubMed Web of Science ®Google Scholar
• Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature447(7145), 661–678 (2007).
   Google Scholar
• Baum AE, Akula N, Cabanero M et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol. Psychiatry (2007) (In Press).
   PubMedGoogle Scholar
• Kato T, Iwayama Y, Kakiuchi C et al. Gene expression and association analyses of LIM (PDLIM5) in bipolar disorder and schizophrenia. Mol. Psychiatry.10(11), 1045–1055 (2005).
   PubMedGoogle Scholar
• Gould TD, Manji HK. The molecular medicine revolution and psychiatry: bridging the gap between basic neuroscience research and clinical psychiatry. J. Clin. Psychiatry65(5), 598–604 (2004).
   PubMed Web of Science ®Google Scholar
• Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J. Affect. Disord.85(3), 259–266 (2005).
   PubMed Web of Science ®Google Scholar
• Keck PE J, Manji HK. Current and emerging treatments for acute mania and long-term prophylaxis for bipolar disorder. In: Neuropsychopharmacology: The Fifth Generation of Progress. Davis KL, Charney D, Coyle JT, Nemeroff C (Eds). Lippincott Williams & Wilkins, PA, USA 1109–1118 (2002).
   Google Scholar
• Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK. Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol. Psychiatry9(8), 734–755 (2004).
   PubMed Web of Science ®Google Scholar
• Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci.116(Pt 7), 1175–1186 (2003).
   PubMed Web of Science ®Google Scholar
• Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc. Am. Soc. Clin. USA93(16), 8455–8459 (1996).
   Google Scholar
• Weaver IC, Cervoni N, Champagne FA et al. Epigenetic programming by maternal behavior. Nat. Neurosci.7(8), 847–854 (2004).
   PubMed Web of Science ®Google Scholar
• Leverich GS, Altshuler LL, Frye MA et al. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J. Clin. Psychiatry64(5), 506–515 (2003).
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh JB, Carlson PJ et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord.9(6), 561–570 (2007).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J. Clin. Psychiatry60(2), 79–88 (1999).
   PubMed Web of Science ®Google Scholar
• Calabresi P, Siniscalchi A, Pisani A, Stefani A, Mercuri NB, Bernardi G. A field potential analysis on the effects of lamotrigine, GP 47779, and felbamate in neocortical slices. Neurology47(2), 557–562 (1996).
   PubMedGoogle Scholar
• Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia27(5), 490–497 (1986).
   PubMed Web of Science ®Google Scholar
• Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW. Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neurons. Synapse24(3), 248–255 (1996).
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Payne JL, Quiroz J et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am. J. Psychiatry161(1), 171–174 (2004).
   PubMed Web of Science ®Google Scholar
• Medina M, Fuertes A, Martin-Aparicio E et al. Protein kinase assays for drug discovery. In: Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors: Drug Discovery and Development. Martinez A, Castro A, Medina M (Eds). John Wiley & Sons, Inc., Hoboken, NJ, USA 190 (2006).
   Google Scholar
• Gould TD, Chen G, Manji HK. Mood stabilizer psychopharmacology. Clin. Neurosci. Res.2, 193–212 (2002).
   PubMedGoogle Scholar
• Gould TD, Manji HK. The Wnt signaling pathway in bipolar disorder. Neuroscientist8(5), 497–511 (2002).
   PubMed Web of Science ®Google Scholar
• Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat. Med.7(5), 541–547 (2001).
   PubMed Web of Science ®Google Scholar